Ariza AR, Álvarez CT

Language: Spanish
References: 19
Page: 52-58
PDF size: 154.95 Kb.

ABSTRACT

We introduce an initial treatment proposal of type 2 diabetes. This paper includes an algorithm based on an American Diabetes Association and European Association for the Study of Diabetes recommendations. The therapeutic proposal was validated and adjusted through the opinions of a group of Mexican physicians and health professionals with special interest in diabetes. We included information of pharmacological features of the drugs and data of clinical trials with high evidence level.

REFERENCES

1. American Association of Clinical Endocrinologists, American College of Endocrinology. The American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus. May/June 2007. http://www.aace.com/pub/pdf/guidelines/DMGuidelines2007.pdf Consultado en julio de 2007.

2. The AGREE Collaboration. Agree Instrument Spanish version. http://www.agreecollaboration.org

3. Battista RN, Hodge MJ. Clinical practice guidelines: between science and art. J Can Med Assoc 1993;148(3):385-8.

4. Nathan DM, Buse JB, Davidson M, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation an adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;49(11):1963-72.

5. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147(6):386-99.

6. Herman LS, Scherstén B, Bitzén PO, et al. Therapeutic comparison of metformin and sulfonilurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994;17(10):1100-9.

7. United Kingdom Prospective Diabetes Study (UKPDS) 13. Relative efficacy of randomly allocated diet, sulfonylureas, insulin or metformin in patients with newly diagnosed noninsulin dependent diabetes followed for three years. BMJ 1995;310(6972):83-89.

8. United Kingdom Prospective Diabetes Study (UKPDS) 34. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998;352(9131):854-65.

9. Simonson DC, Kourides IA, Feinglos M, et al. Efficacy, safety and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care 1997;20(4):597-606.

10. Sönksen PH, Lowy C, Perkins JR, Lim HS. Non-insulin-dependent diabetes: 10-year outcome in relation to initial response to diet and subsequent sulfonylurea therapy. Diabetes Care 1984;7 (Suppl 1):59-66.

11. Turner R, Stratton I, Horton V, et al. UKPDS 25: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997;350(9087):1288-93.

12. Maggs DG, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized double-blind placebo controlled trial. Ann Intern Med 1998;128(3):176-85.

13. Patel J, Anderson R, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999;1(3):165-72.

14. Goldberg RB, Einhorn D, Lucas CP, et al. A randomized placebo- controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998;21(11):1897-903.

15. Wolffenbuttel B, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999;22(3):463-7.

16. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356(24):2457-71.

17. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298(10):1189-95.

18. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;91(9):3349-54.

19. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31(1):173-5.